NEURONETICS INC (STIM)
US64131A1051 - Common Stock
STIM gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 195 industry peers in the Health Care Equipment & Supplies industry. STIM may be in some trouble as it scores bad on both profitability and health. STIM is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
STIM had negative earnings in the past year.
STIM had a negative operating cash flow in the past year.
STIM had negative earnings in each of the past 5 years.
In the past 5 years STIM always reported negative operating cash flow.
1.2 Ratios
With a Return On Assets value of -26.06%, STIM perfoms like the industry average, outperforming 49.74% of the companies in the same industry.
STIM's Return On Equity of -88.29% is on the low side compared to the rest of the industry. STIM is outperformed by 64.10% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -26.06% | ||
| ROE | -88.29% | ||
| ROIC | N/A |
ROA(3y)-26.65%
ROA(5y)-28.76%
ROE(3y)-63.33%
ROE(5y)-71.65%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of STIM (75.13%) is better than 86.15% of its industry peers.
STIM's Gross Margin has been stable in the last couple of years.
STIM does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 75.13% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.81%
GM growth 5Y-1.05%
2. Health
2.1 Basic Checks
STIM does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for STIM has been increased compared to 1 year ago.
STIM has more shares outstanding than it did 5 years ago.
The debt/assets ratio for STIM is higher compared to a year ago.
2.2 Solvency
STIM has an Altman-Z score of -3.16. This is a bad value and indicates that STIM is not financially healthy and even has some risk of bankruptcy.
STIM has a Altman-Z score of -3.16. This is in the lower half of the industry: STIM underperforms 64.10% of its industry peers.
STIM has a Debt/Equity ratio of 1.73. This is a high value indicating a heavy dependency on external financing.
STIM's Debt to Equity ratio of 1.73 is on the low side compared to the rest of the industry. STIM is outperformed by 85.13% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.73 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -3.16 |
ROIC/WACCN/A
WACC10.67%
2.3 Liquidity
A Current Ratio of 4.73 indicates that STIM has no problem at all paying its short term obligations.
STIM has a better Current ratio (4.73) than 66.15% of its industry peers.
A Quick Ratio of 4.33 indicates that STIM has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 4.33, STIM is in the better half of the industry, outperforming 72.82% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.73 | ||
| Quick Ratio | 4.33 |
3. Growth
3.1 Past
STIM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 22.41%, which is quite impressive.
STIM shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 9.41%.
The Revenue has been growing slightly by 6.21% on average over the past years.
EPS 1Y (TTM)22.41%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q36.67%
Revenue 1Y (TTM)9.41%
Revenue growth 3Y13.16%
Revenue growth 5Y6.21%
Revenue growth Q2Q11.62%
3.2 Future
The Earnings Per Share is expected to grow by 17.07% on average over the next years. This is quite good.
Based on estimates for the next years, STIM will show a quite strong growth in Revenue. The Revenue will grow by 15.55% on average per year.
EPS Next Y11.82%
EPS Next 2Y18%
EPS Next 3Y17.07%
EPS Next 5YN/A
Revenue Next Year11.62%
Revenue Next 2Y12.3%
Revenue Next 3Y13.27%
Revenue Next 5Y15.55%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
STIM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for STIM. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as STIM's earnings are expected to grow with 17.07% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18%
EPS Next 3Y17.07%
5. Dividend
5.1 Amount
STIM does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NEURONETICS INC
NASDAQ:STIM (4/24/2024, 7:00:00 PM)
After market: 3.8 +0.05 (+1.33%)3.75
-0.11 (-2.85%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap111.60M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -26.06% | ||
| ROE | -88.29% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 75.13% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.62
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.73 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 4.73 | ||
| Quick Ratio | 4.33 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)22.41%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y11.82%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)9.41%
Revenue growth 3Y13.16%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y